These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25281617)

  • 41. Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo.
    Chou ST; Leng Q; Scaria P; Woodle M; Mixson AJ
    Cancer Gene Ther; 2011 Oct; 18(10):707-16. PubMed ID: 21818135
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Programmably tiling rigidified DNA brick on gold nanoparticle as multi-functional shell for cancer-targeted delivery of siRNAs.
    Xue C; Hu S; Gao ZH; Wang L; Luo MX; Yu X; Li BF; Shen Z; Wu ZS
    Nat Commun; 2021 May; 12(1):2928. PubMed ID: 34006888
    [TBL] [Abstract][Full Text] [Related]  

  • 43. U1 Adaptors Suppress the
    Tsang AT; Dudgeon C; Yi L; Yu X; Goraczniak R; Donohue K; Kogan S; Brenneman MA; Ho ES; Gunderson SI; Carpizo DR
    Mol Cancer Ther; 2017 Aug; 16(8):1445-1455. PubMed ID: 28377488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
    Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
    Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.
    Mook OR; Baas F; de Wissel MB; Fluiter K
    Mol Cancer Ther; 2007 Mar; 6(3):833-43. PubMed ID: 17363479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Milk exosomes - Natural nanoparticles for siRNA delivery.
    Aqil F; Munagala R; Jeyabalan J; Agrawal AK; Kyakulaga AH; Wilcher SA; Gupta RC
    Cancer Lett; 2019 May; 449():186-195. PubMed ID: 30771430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
    Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
    Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Use of Star Polymer Nanoparticles for the Delivery of siRNA to Mouse Orthotopic Pancreatic Tumor Models.
    McCarroll JA; Sharbeen G; Kavallaris M; Phillips PA
    Methods Mol Biol; 2019; 1974():329-353. PubMed ID: 31099013
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.
    Dudek H; Wong DH; Arvan R; Shah A; Wortham K; Ying B; Diwanji R; Zhou W; Holmes B; Yang H; Cyr WA; Zhou Y; Shah A; Farkiwala R; Lee M; Li Y; Rettig GR; Collingwood MA; Basu SK; Behlke MA; Brown BD
    Mol Ther; 2014 Jan; 22(1):92-101. PubMed ID: 24089139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. siRNA Nanoparticles for Ultra-Long Gene Silencing In Vivo.
    Lee SK; Tung CH
    Methods Mol Biol; 2016; 1372():113-20. PubMed ID: 26530919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
    Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
    Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
    Mangala LS; Rodriguez-Aguayo C; Bayraktar E; Jennings NB; Lopez-Berestein G; Sood AK
    Methods Mol Biol; 2021; 2372():157-168. PubMed ID: 34417750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Magnetic Resonance Spectroscopy of siRNA-Based Cancer Therapy.
    Penet MF; Chen Z; Mori N; Krishnamachary B; Bhujwalla ZM
    Methods Mol Biol; 2016; 1372():37-47. PubMed ID: 26530913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
    Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Silencing KRAS overexpression in arsenic-transformed prostate epithelial and stem cells partially mitigates malignant phenotype.
    Ngalame NN; Tokar EJ; Person RJ; Waalkes MP
    Toxicol Sci; 2014 Dec; 142(2):489-96. PubMed ID: 25273566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
    McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
    Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.